Johanna Estrada

BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.

P. Szankasi, D. Marin, B. Druker, 2013, Blood.

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.

R. Larson, R. Baron, M. Baccarani, 2014, Cancer cell.